In a much anticipated announcement during the Replenishment Conference in New York on Monday and Tuesday this week, the Obama Administration revealed a $4 billion pledge to the Global Fund to Fight AIDS, Tuberculosis and Malaria over the next three years.
8 hours ago | Science Speaks
MORE than 500 000 HIV positive people are in urgent need of anti-retro viral (ART) drugs as government frantically tries to source funds to address the crisis, a senior health ministry official has said. Elderly people are the main target because they are not gainfully employed, he said.
29 September 2015 | New Zimbabwe via Allafrica.com
A new report shows that the Global Fund partnership has made remarkable gains against HIV, tuberculosis and malaria by supporting programs that have saved more than 17 million lives.
22 September 2015 | Global Fund
AUSTRALIANS at risk of HIV are being forced to import a potentially life-changing drug because it is too expensive there. The pre-exposure prophylaxis Truvada costs about $1300 on the overseas market compared to $10,000 a year in Australia.
15 September 2015 | Sunshine Coast Daily
A major Indian supplier of tuberculosis drugs to developing countries has been severely criticized by the World Health Organization for inadequate manufacturing standards and poor testing procedures. The United Nations agency issued a warning letter to Mumbai-based Svizera Labs, part of Maneesh Pharmaceuticals, stating that the approval and use of its products would be suspended if "critical and major observations are not corrected within a reasonable time frame".
15 September 2015 | Medical Daily
People living with HIV and their healthcare providers welcome the anticipated benefits of substituting tenofovir alafenamide fumarate (TAF) for tenofovir disoproxil fumarate (TDF). We would like to ensure that all people living with HIV have access to these new formulations that may lower the risk of bone and kidney toxicity in accordance with phase III clinical trials.
10 September 2015 | TAG
Partners in global health began discussions today aimed at shaping a new strategy for the Global Fund partnership to accelerate the end of AIDS, tuberculosis and malaria as epidemics. The Partnership Forum brought together over 10 participants from communities affected by the diseases, civil society, nongovernmental organizations, governments, technical partners and the private sector to a two-day gathering to influence the development of the Global Fund's new strategy. Recent scientific advances and growing experience in implementation mean there is an historic opportunity to end the three diseases as public health threats. Aida Kurtovic, the Vice-Chair of the Global Fund Board, said: "We need an ambitious strategy that puts us in a position to eliminate the three diseases."
08 September 2015 | AllAfrica.com
The following letter, supported by a range of HIV charities, has been published in the Daily Telegraph. The letter to the editors warning on the impact of public health cuts, and calling for investment in public health in the Spending Review in order to secure the future of the NHS.
02 September 2015 | Blenheim / Daily Telegraph
New York City has quietly shuttered its busiest STD clinic, and the city has cut hundreds of thousands of free HIV tests since 2010. City officials blame a shrinking budget, but AIDS activists say it’s putting many people at risk.
01 September 2015 | BuzzFeed
Like many physicians that specialize in hepatitis C virus (HCV) treatment, I have spent the last few years advising many of my patients with chronic HCV infection to defer treatment and wait for new therapies. Patients, advocacy groups, and physicians closely followed the development of [these new therapies] in eager anticipation of US Food and Drug Administration (FDA) approval and, for most patients, the possibility of a cure of their HCV infection. However, this eager anticipation morphed into uneasy concern as, along with FDA approval, drug pricing was announced.
26 August 2015 | Clinical Liver Disease